The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis

Table 3

Initial MM vs. recurrent MM patients treated with T-VAD.

Study	Data year	Tumor stage; I/II/III	Patients		Age (year)		Comparison		Test conditions and units
			Initial	Relapse	Initial	Relapse	Initial	Relapse
Zhai et al., 2012 [35]	2004−2011	0/13/29	30	7	56	56	T-VAD	T-VAD	ELISA; VEGF (pg/ml)
Du et al.,; 2014 [36]	Not clear	0/ 6/32	26	7	58	58	T-VAD	T-VAD	VEGF (pg/ml)

Zhang N, Shen Ti, editor. Blood disease diagnosis and efficacy standards. Version 2. Beijing: Science Press, 1998;373.376 [37]; Zhang Zhinan, Sen Ti. Blood disease diagnosis and efficacy standards. 3rd edition Beijing: Science Press. 2007, 232−235 [38]; Durie BG Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features response to treatment and survival. Cancer, 1975, 36:842−854 [39]; Blood Physicians Association, Hematology Branch of Chinese Medical Association, Multiple myeloma working group in China. China guidelines for diagnosis and treatment of multiple myeloma (revised in 2013). Chin J Int Med, 2013, 52(9):791−795 [40].